eHealth Initiative

ehidc.org

eHealth Initiative and Foundation (eHI) is a Washington DC-based, independent, non-profit organization whose mission is to drive improvements in the quality, safety, and efficiency of healthcare through information technology. eHI is a multi-stakeholder collaborative, convening executives from every group in healthcare, to discuss, identify, and share best practices that transform the delivery of healthcare. Working with its membership, eHI advocates for the use of health IT that is practical, sustainable, and addresses stakeholder needs, particularly those of patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CLARIFY HEALTH LAUNCHES NEXT-GENERATION ANALYTICS TO ASSIST PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

Clarify Health | July 01, 2020

news image

Clarify Health, a leading healthcare analytics company, announced that its life sciences software, Clarify Launch, now includes innovative enhancements that give brand teams a faster and more effective way to identify market opportunities to drive growth. The ability to explore over 300 million longitudinal patient care journeys using Clarify Launch offers brand teams rapid access to actionable insights within specific patient populations. Clarify brings first-of-their-kind patient segmentation,...

Read More

Pharma Tech

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19

Pfizer | November 10, 2020

news image

Pfizer Inc.and BioNTech SE today reported their mRNA-based antibody up-and-comer, BNT162b2, against SARS-CoV-2 has exhibited proof of adequacy against COVID-19 in members without earlier proof of SARS-CoV-2 contamination, in view of the principal break viability examination led on November 8, 2020 by an outer, free Data Monitoring Committee (DMC) from the Phase 3 clinical investigation. After conversation with the FDA, the organizations as of late chosen to drop the 32-case between time examinat...

Read More

Pharmacy Market

EVERGREEN THERAGNOSTICS INCREASES ALPHA RADIOPHARMACEUTICAL PRODUCTION CAPABILITIES

Evergreen Theragnostics, Inc. | July 17, 2021

news image

Evergreen Theragnostics, Inc., a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) has started a major strategic expansion at its Springfield, NJ manufacturing facility. Evergreen has already started expanding to build a GMP state-of-the-art alpha emitter production center, incorporated into Evergreen's current facility, with the Evergreen Springfield Facility scheduled to open within the next two months. The expansion, which is scheduled t...

Read More

Business Insights

CULLINAN ONCOLOGY FORMS STRATEGIC COLLABORATION AGREEMENT WITH MOUNT SINAI TO ADVANCE ORAL HPK1 PROTEIN DEGRADER FOR CANCER TREATMENT

Cullinan Oncology, Inc. | January 10, 2022

news image

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to develop novel small molecule immune modulators.​ This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor...

Read More
news image

CLARIFY HEALTH LAUNCHES NEXT-GENERATION ANALYTICS TO ASSIST PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

Clarify Health | July 01, 2020

Clarify Health, a leading healthcare analytics company, announced that its life sciences software, Clarify Launch, now includes innovative enhancements that give brand teams a faster and more effective way to identify market opportunities to drive growth. The ability to explore over 300 million longitudinal patient care journeys using Clarify Launch offers brand teams rapid access to actionable insights within specific patient populations. Clarify brings first-of-their-kind patient segmentation,...

Read More
news image

Pharma Tech

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19

Pfizer | November 10, 2020

Pfizer Inc.and BioNTech SE today reported their mRNA-based antibody up-and-comer, BNT162b2, against SARS-CoV-2 has exhibited proof of adequacy against COVID-19 in members without earlier proof of SARS-CoV-2 contamination, in view of the principal break viability examination led on November 8, 2020 by an outer, free Data Monitoring Committee (DMC) from the Phase 3 clinical investigation. After conversation with the FDA, the organizations as of late chosen to drop the 32-case between time examinat...

Read More
news image

Pharmacy Market

EVERGREEN THERAGNOSTICS INCREASES ALPHA RADIOPHARMACEUTICAL PRODUCTION CAPABILITIES

Evergreen Theragnostics, Inc. | July 17, 2021

Evergreen Theragnostics, Inc., a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) has started a major strategic expansion at its Springfield, NJ manufacturing facility. Evergreen has already started expanding to build a GMP state-of-the-art alpha emitter production center, incorporated into Evergreen's current facility, with the Evergreen Springfield Facility scheduled to open within the next two months. The expansion, which is scheduled t...

Read More
news image

Business Insights

CULLINAN ONCOLOGY FORMS STRATEGIC COLLABORATION AGREEMENT WITH MOUNT SINAI TO ADVANCE ORAL HPK1 PROTEIN DEGRADER FOR CANCER TREATMENT

Cullinan Oncology, Inc. | January 10, 2022

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to develop novel small molecule immune modulators.​ This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us